Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inmune Bio (INMB) Change in Accured Expenses (2018 - 2025)

Inmune Bio (INMB) has disclosed Change in Accured Expenses for 8 consecutive years, with $893000.0 as the latest value for Q4 2025.

  • Quarterly Change in Accured Expenses rose 122.04% to $893000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.9 million through Dec 2025, up 236.2% year-over-year, with the annual reading at $1.9 million for FY2025, 236.2% up from the prior year.
  • Change in Accured Expenses hit $893000.0 in Q4 2025 for Inmune Bio, up from -$170000.0 in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $3.1 million in Q3 2023 to a low of -$4.1 million in Q4 2024.
  • Historically, Change in Accured Expenses has averaged $125450.0 across 5 years, with a median of $88000.0 in 2022.
  • Biggest five-year swings in Change in Accured Expenses: tumbled 7013.33% in 2022 and later surged 4041.67% in 2025.
  • Year by year, Change in Accured Expenses stood at -$488000.0 in 2021, then surged by 226.84% to $619000.0 in 2022, then tumbled by 229.89% to -$804000.0 in 2023, then plummeted by 403.86% to -$4.1 million in 2024, then surged by 122.04% to $893000.0 in 2025.
  • Business Quant data shows Change in Accured Expenses for INMB at $893000.0 in Q4 2025, -$170000.0 in Q3 2025, and $473000.0 in Q2 2025.